Abstract:Objectives: To study the molecular epidemiology of clinical metallo-beta-lactamase (MBL)-producing Enterobacteriaceae isolates in China and to evaluate the antimicrobial susceptibility of MBL-Enterobacteriaceae isolates to aztreonam-avibactam. Methods: Bacterial speciation was determined using matrix-assisted laser desorption/ionization time-off-light mass spectrometry. PCR was used to screen for common carbapenemase genes. Antimicrobial susceptibility testing of common clinical antibiotics and aztreonam-avibactam was performed using the standard broth microdilution method. Results: A total of 161 MBL-Enterobacteriaceae isolates were included, with Klebsiella pneumoniae (n = 73, 45.4%) and Escherichia coli (n = 53, 32.9%) being the most common species. Among the 161 isolates, bla(NDM) (n = 151), bla(IMP) (n = 13), and bla(VIM) (n = 2) were detected, including five strains (3.1%) co-harboring two MBLs. MBL-Enterobacteriaceae isolates frequently contained two (n = 55, 34.2%) or more (n = 89, 55.3%) additional serine beta-lactamase genes(bla(KPC), bla(CTX-M), bla(TEM), or bla(SHV)). Antimicrobial susceptibility testing showed that 81.4% of isolates (n = 131) were resistant to aztreonam. The rates of resistance to cefazolin, ceftazidime, ceftriaxone, cefotaxime, ampicillin-sulbactam, amoxicillin-clavulanic acid, and piperacillintazobactam were all over 90%. The addition of avibactam (4 mu g/ml) significantly reduced the minimum inhibitory concentrations (MICs) of the aztreonam-resistant isolates by more than 8-fold (range <= 0.125 to 4 mu g/ml), with a MIC50/MIC90 of <= 0.125/1 mu g/ml among the 131 isolates. Overall, 96.9% (n = 156) of the total isolates were inhibited at an aztreonam-avibactam concentration of <= 1 mu g/ml. Univariate and multivariate logistic regression analysis found that in patients with MBL-Enterobacteriaceae infections, the presence of pre-existing lung disease (adjusted odds ratio 8.267, 95% confidence interval 1.925-28.297; p = 0.004) was associated with a hazard effect on worse disease outcomes. Conclusions: The combined use of aztreonam-avibactam is highly potent against MBL-Enterobacteriaceae and may serve as a new candidate for the treatment of infections caused by MBL-Enterobacteriaceae in China. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System

A Real‐World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database

Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database

Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

Safety evaluation of ceftazidime/avibactam based on FAERS database

The Safety of Aztreonam Versus Ceftazidime in Patients Labeled With Penicillin Allergy: A Cohort Study

In Vitro Activity of Aztreonam-Avibactam Against Metallo--lactamase-producing Enterobacteriaceae-A Multicenter Study in China

Analysis on 522 cases of antibacterial-related adverse drug reaction/event reports

A randomized controlled clinical study of aztraonam in treatment of 60 elderly patients with low respiratory tract bacterial infections

A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database

A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database

Analysis on 198 cases adverse drug reaction/event reports of azithromycin

Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag

Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae

Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase‐Inhibitor Anastrozole Treatment

Antibiotics-associated pseudomembranous colitis: a disproportionality analysis of the US food and drug administration adverse event reporting system (FAERS) database

A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database

Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023